胃癌 Open Access
Copyright ©The Author(s) 2003. Published by Baishideng Publishing Group Inc. All rights reserved.
世界华人消化杂志. 2003-01-15; 11(1): 36-38
在线出版日期: 2003-01-15. doi: 10.11569/wcjd.v11.i1.36
胃癌P-糖蛋白表达与化疗效果相关
陈春燕, 朱兆华
陈春燕, 朱兆华, 中山大学附属第二医院消化内科 广东省广州市 510120
陈春燕, 女, 1974-04-14生, 福建省福州市人, 汉族.1999年中山医科大学本科毕业, 2002年硕士毕业, 从事胃肠疾病的研究.
通讯作者: 朱兆华, 510120, 广东省广州市沿江西路107号, 中山大学附属第二医院消化内科.
电话: 020-81332390
收稿日期: 2002-07-06
修回日期: 2002-07-25
接受日期: 2002-07-30
在线出版日期: 2003-01-15

目的: 分析P-糖蛋白表达的临床意义, 其表达与化疗疗效的关系, 通过检测P-糖蛋白的表达而指导临床对胃癌患者的化疗.

方法: 应用SP免疫组化方法检测101例胃癌石蜡标本, 79例胃癌旁组织, 15例正常胃组织.

结果: P-糖蛋白在正常胃黏膜、胃癌旁组织、胃癌组织中的表达分别为13%, 22%, 43%, P<0.05. P-糖蛋白的表达在高分化、中分化胃癌中(58%, 80%)显著高于低分化、未分化胃癌(36%, 25%), P<0.05. P-糖蛋白阴性组有化疗患者和无化疗患者两组的术后累积生存率有显著差异, P<0.01.

结论: P-糖蛋白的表达与胃癌的分化程度有关, 影响术后化疗疗效.

关键词: N/A

引文著录: 陈春燕, 朱兆华. 胃癌P-糖蛋白表达与化疗效果相关. 世界华人消化杂志 2003; 11(1): 36-38
Relationship between expression of P-glycoprotein and efficacy of chemotherapy in gastric cancer
Chun-Yan Chen, Zhao-Hua Zhu
Chun-Yan Chen, Zhao-Hua Zhu, Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guandong Province, China
Correspondence to: Zhao-Hua Zhu, Department of Gastroenterology. The Second Affiliated Hospital, Sun Yat-Sen University. 107 Yan Jiang lu, Guangzhou 510120, Guandong Province, China.
Received: July 6, 2002
Revised: July 25, 2002
Accepted: July 30, 2002
Published online: January 15, 2003

AIM: To investigate the significance of the expression of P-glycoprotein and the relationship between its expression and the efficacy of chemotherapy in patients with gastric cancer.

METHODS: P-glycoprotein was examined by immunohistochemical staining in 101 specimens of paraffin embedded gastric cancer tissues.

RESULTS: The expression rates of P-glycoprotein in normal gastric mucosa, paracancerous tissues and gastric cancer tissues were 13%, 22% and 43%, respectively (P < 0.05). The expression rates of P-glycoprotein in the highly and moderately differentiated tumors (58% and 80%, respectively) were significantly higher than those in the lowly and poorly differentiated tumors (36% and 25%, respectively) (P < 0.01). The postoperative cumulative survival rate of the patients receiving chemotherapy was significantly higher than that of the patients without chemotherapy in P-glycoprotein-negative patients with gastric cancer (P < 0.01).

CONCLUSION: The expression of P-glycoprotein was correlated with the degree of tumor differentiation and influenced the efficacy of postoperative chemotherapy.

Key Words: N/A


0 引言

多药耐药(multidrug resistance, MDR)是导致胃癌对抗肿瘤药物产生耐药的重要原因之一[1-5]. 他编码的P-糖蛋白(p-glycoprotein, P-gp)是一种能量依赖性药物排出泵, 通过ATP提供能量, 可将抗肿瘤药物由胞内泵出胞外, 使其细胞毒作用减弱或消失而出现耐药性[6-10]. 我们检测P-gp在胃癌中的表达, 分析表达的临床意义, 表达与化疗疗效的关系.

1 材料和方法
1.1 材料

随机抽取胃癌石蜡标本101例, 胃癌旁组织79例, 其中88例胃癌患者已知其生存期. 再随机抽取正常胃组织标本15例作为对照.

1.2 方法

采用SP(streptacidin-peroxidose, 链霉菌抗生物素蛋白-过氧化物酶)方法. DAB染色, 用PBS代替一抗作阴性对照, 已知P-gp阳性结肠癌标本作为阳性对照. P-gp单抗购自福州迈新公司, 结果判断以细胞膜上和(或)细胞质内出现棕黄色染色为阳性细胞, 整张切片中阳性细胞数占≥5%即为阳性.

统计学处理 计数资料率的比较使用x2检验, 计量资料两组均数的比较使用t检验, 累积生存率的比较使用Log-rank检验.

2 结果

胃癌组织P-gp阳性率显著高于正常胃黏膜(42.6% vs 13.3%, P<0.01)和胃癌旁组织(42.6%vs 21.5%, P<0.05)但在正常胃黏膜与胃癌旁组织间无显著差异(13.3% vs 21.5%, P>0.05). P-gp的表达与胃癌患者的性别、年龄、肿瘤部位、肿瘤大小、大体类型无关(P>0.05).

2.1 P-gp与TNM分期、肿瘤病理的关系

P-gp的表达与肿瘤浸润深度、淋巴结转移、远处转移、TNM分期无关(P>0.05). P-gp的表达与胃癌病理学类型无关(P>0.05, 表1), 但与肿瘤分化程度相关(r=0.24, P<0.01). 即分化程度差的胃癌其P-gp表达率降低.

表1 P-gp与肿瘤病理学关系.
病理nP-gp
阳性阴性阳性率%
管状腺癌2215768
低分化腺癌59223737
黏液细胞癌51420
黏液腺癌114736
未分化癌41325
肿瘤分化
127558b
108280
75274836
41325
2.2 P-gp与术后化疗的关系

有术后化疗者共58例, 使用化疗药物以氟脲嘧啶类化疗药(包括5-Fu, UFT, FTL, FT207)与生化调节剂醛氢叶酸为主, 其余化疗药包括阿霉素、丝裂霉素、铂类等. 经Log-rank 检验, 显示P-gp阴性组有化疗和无化疗两组术后累积生存率有显著差异(P<0.01, 表2). 有化疗组术后累积生存率高于无化疗组. P-gp阳性组有化疗和无化疗两组术后累积生存率无显著差异(P>0.05).

表2 P-gp与术后累积生存率(%).
T/moP-gp阴性
P-gp阳性
化疗组(n = 27)无化疗组(n = 21)化疗组(n = 31)无化疗组(n = 9)
1259b243942
2444b122521
3627b61714
4813b680
3 讨论

我们发现P-gp在胃癌中的表达高于正常胃黏膜及胃癌旁组织, 其表达与胃癌的生物学行为无关, 与文献[11-13]报道相符, P-gp的表达与分化程度相关, 高、中分化胃癌表达高于低、未分化[14-16]. 此种现象可以说明, 对于分化差的胃癌患者化疗较敏感, 而分化较好的胃癌患者化疗不敏感[15]. P-gp的表达是导致胃癌产生耐药的原因之一, 我们通过对胃癌组织切片P-gp的检测, 发现P-gp阴性组有术后化疗患者的术后累积生存率显著高于无术后化疗组, 而P-gp阳性组的术后化疗患者与无术后化疗患者的术后累积生存率无显著差异. 由此推测不表达P-gp的患者由于对化疗较敏感, 所以化疗能提高生存率, 而P-gp阳性的患者由于已存在原发性耐药, 对化疗药物不敏感, 所以即使进行术后化疗, 亦不能提高生存率[16-21]. 同理, 对于不表达P-gp的患者, 在术后化疗过程中是否会产生继发性耐药?如果我们能对胃癌患者在化疗前后行P-gp检测则能进一步说明这个问题.

当P-gp表达阳性者, 是否就不予化疗?近年来对P-gp研究的深入, 发现能逆转P-gp的耐药方法有:(1)抑制P-gp的功能, 使其作用下降或不能发挥作用, 包括钙通道阻滞剂[22,23], 抗雌激素药[24,25], 环胞霉素[26], 或用免疫治疗的方法, 如用某种P-gp抗体封闭P-gp, 从而改变MDR细胞对化疗药物的主动外排功能, 逆转细胞的耐药性[27].(2)降低蛋白的合成, 如调节蛋白激酶PKA的活性, 抑制mdr的转录, 使P-gp合成降低[28,29].(3)针对转录水平, 即mRNA水平, 如用反义核酸在mRNA水平减少相应蛋白质的表达, 或用核酶直接切割靶RNA, 阻断其表达, 达到抑制蛋白产物产生的目的[30-32]. 钙通道阻滞剂维拉帕米(VER)已被用于临床[33]. 但其心血管系毒副作用, 限制了他的用量以及在临床中的应用[34]. 尽管P-gp的表达影响化疗的效果, 但多药耐药的机制是多样且复杂的.

编辑: N/A

1.  俞 丽芬, 吴 云林. 消化道肿瘤与多药耐药基因的临床相关性研究进展. 华人消化杂志. 1998;6:915-916.  [PubMed]  [DOI]
2.  Shi YQ, Xiao B, Miao JY, Zhao YQ, You H, Fan DM. Construction of eukaryotic expression vector pBK-fas and MDR reversal test of drug-resistant gastric cancer cells. Shijie Huaren Xiaohua Zazhi. 1999;7:309-312.  [PubMed]  [DOI]
3.  Wuchter C, Leonid K, Ruppert V, Schrappe M, Büchner T, Schoch C, Haferlach T, Harbott J, Ratei R, Dörken B. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica. 2000;85:711-721.  [PubMed]  [DOI]
4.  DeGeorge JJ, Ahn CH, Andrews PA, Brower ME, Giorgio DW, Goheer MA, Lee-Ham DY, McGuinn WD, Schmidt W, Sun CJ. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol. 1998;41:173-185.  [PubMed]  [DOI]
5.  Chen GK, Lacayo NJ, Durán GE, Wang Y, Bangs CD, Rea S, Kovacs M, Cherry AM, Brown JM, Sikic BI. Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. Genes Chromosomes Cancer. 2002;34:372-383.  [PubMed]  [DOI]
6.  Meijer GA, Schroeijers AB, Flens MJ, Meuwissen SG, van der Valk P, Baak JP, Scheper RJ. Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis. J Clin Pathol. 1999;52:450-454.  [PubMed]  [DOI]
7.  Hoffmann J, Schmidt-Peter P, Hänsch W, Naundorf H, Bunge A, Becker M, Fichtner I. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas. Clin Cancer Res. 1999;5:2198-2204.  [PubMed]  [DOI]
8.  Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S, Arisio R, Scheper RJ, Kool M, Scheffer GL. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res. 1999;5:2798-2805.  [PubMed]  [DOI]
9.  Ruiz Gómez MJ, Gil L, Souviron A, Martínez Morillo M. Multidrug resistance increment in a human colon carcinoma cell line by colchicine. J Physiol Biochem. 2000;56:33-38.  [PubMed]  [DOI]
10.  Maraldi NM, Zini N, Santi S, Scotlandi K, Serra M, Baldini N. P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells. Biol Cell. 1999;91:17-28.  [PubMed]  [DOI]
11.  Ni CRExpression significance of GST-p, P-gp, Top-Ⅱ and nm23H1 in gastric carcinoma. Shijie Huaren Xiaohua Zazhi. 2001;9:897-901.  [PubMed]  [DOI]
12.  Liu ZM, Shou NH. Expression significance of mdr1 gene in gastric carcinoma tissue. Shijie Huaren Xiaohua Zazhi. 1999;7:145-146.  [PubMed]  [DOI]
13.  赵 行远, 夏 传生, 吴 建平, 侯 炜, 刘 运芳. MDRI产物P-gp在结肠肿瘤中表达的意义. 世界华人消化杂志. 1999;7:991.  [PubMed]  [DOI]
14.  Lo Muzio L, Staibano S, Pannone G, Mignogna MD, Serpico R, Rubini C, Fioroni M, Fanali S, Piattelli A. The human multidrug resistance gene (MDR-1): immunocytochemical detection of its expression in oral SCC. Anticancer Res. 2000;20:2891-2897.  [PubMed]  [DOI]
15.  Tokunaga Y, Hosogi H, Hoppou T, Nakagami M, Tokuka A, Ohsumi K. Effects of MDR1/P-glycoprotein expression on prognosis in advanced colorectal cancer after surgery. Oncol Rep. 2001;8:815-819.  [PubMed]  [DOI]
16.  Xie ZJ, Yang XF, Gu ZY, Wu QL. P-glycoprotein expression in squamous cell carcinoma of the oral and maxillofacial region. Chin J Dent Res. 2000;3:23-26.  [PubMed]  [DOI]
17.  Galani E, Sgouros J, Petropoulou C, Janinis J, Aravantinos G, Dionysiou-Asteriou D, Skarlos D, Gonos E. Correlation of MDR-1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients. Anticancer Res. 2002;22:2275-2280.  [PubMed]  [DOI]
18.  Tafuri A, Gregorj C, Petrucci MT, Ricciardi MR, Mancini M, Cimino G, Mecucci C, Tedeschi A, Fioritoni G, Ferrara F. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood. 2002;100:974-981.  [PubMed]  [DOI]
19.  Soni S, Pande P, Shukla NK, Ralhan R. Coexpression of Ets-1 and p53 in oral carcinomas is associated with P-glycoprotein expression and poor prognosis. J Cancer Res Clin Oncol. 2002;128:336-342.  [PubMed]  [DOI]
20.  Liang JA, Shiau YC, Yang SN, Lin FJ, Kao A, Lee CC. Prediction of chemotherapy response in untreated malignant lymphomas using technetium-99m methoxyisobutylisonitrile scan: comparison with P-glycoprotein expression and other prognostic factors. A preliminary peport. Jpn J Clin Oncol. 2002;32:140-145.  [PubMed]  [DOI]
21.  Damiani D, Michelutti A, Michieli M, Masolini P, Stocchi R, Geromin A, Ermacora A, Russo D, Fanin R, Baccarani M. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. Br J Haematol. 2002;116:519-527.  [PubMed]  [DOI]
22.  Moins N, Cayre A, Chevillard S, Maublant J, Verrelle P, Finat-Duclos F. Effects of MDR reversing agent combinations on the 3H-daunomycin accumulation in drug-sensitive and drug-resistant human cancer cells. Anticancer Res. 2000;20:2617-2623.  [PubMed]  [DOI]
23.  Dale IL, Tuffley W, Callaghan R, Holmes JA, Martin K, Luscombe M, Mistry P, Ryder H, Stewart AJ, Charlton P. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer. 1998;78:885-892.  [PubMed]  [DOI]
24.  Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer. 1999;86:300-311.  [PubMed]  [DOI]
25.  Nathan FE, Berd D, Sato T, Mastrangelo MJ. Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma. Cancer. 2000;88:79-87.  [PubMed]  [DOI]
26.  Mealey KL, Barhoumi R, Burghardt RC, McIntyre BS, Sylvester PW, Hosick HL, Kochevar DT. Immunosuppressant inhibition of P-glycoprotein function is independent of drug-induced suppression of peptide-prolyl isomerase and calcineurin activity. Cancer Chemother Pharmacol. 1999;44:152-158.  [PubMed]  [DOI]
27.  Parasrampuria DA, Lantz MV, Birnbaum JL, Vincenti FG, Benet LZ. Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation. J Clin Pharmacol. 2002;42:304-311.  [PubMed]  [DOI]
28.  Parissenti AM, Gannon BR, Villeneuve DJ, Kirwan-rhude AF, Chadderton A, Glück S. Lack of modulation of MDR1 gene expression by dominant inhibition of cAMP-dependent protein kinase in doxorubicin-resistant MCF-7 breast cancer cells. Int J Cancer. 1999;82:893-900.  [PubMed]  [DOI]
29.  Han Y, Shi YQ, Zheng Y, Nie YZ, Zhang HB, Zhang ML, Pan BR, Fan DM. Protein kinase C is related to multidrug resistance induced by MGr1-Ag. Shijie Huaren Xiaohua Zazhi. 2001;9:517-521.  [PubMed]  [DOI]
30.  Prakash TP, Kawasaki AM, Johnston JF, Graham MJ, Condon TP, Manoharan M. Antisense properties of 2'-O-dimethylaminooxyethyl (2'-O-DMAOE) oligonucleotides. Nucleosides Nucleotides Nucleic Acids. 2001;20:829-832.  [PubMed]  [DOI]
31.  Aoyagi S, Narlikar G, Zheng C, Sif S, Kingston RE, Hayes JJ. Nucleosome remodeling by the human SWI/SNF complex requires transient global disruption of histone-DNA interactions. Mol Cell Biol. 2002;22:3653-3662.  [PubMed]  [DOI]
32.  Rackstraw BJ, Stolnik S, Davis SS, Bignotti F, Garnett MC. Development of multicomponent DNA delivery systems based upon poly(amidoamine)-PEG co-polymers. Biochim Biophys Acta. 2002;1576:269-286.  [PubMed]  [DOI]
33.  Benderra Z, Morjani H, Trussardi A, Manfait M. Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein. Int J Oncol. 1998;12:711-715.  [PubMed]  [DOI]
34.  马 强, 张 振书, 王 群英. 大肠癌多药耐药性的逆转. 世界华人消化杂志. 2001;9:822-825.  [PubMed]  [DOI]